+

Shareholder Information

Number­ of ­Existing ­Ordinary­ Shares in issue: ­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­84,068,923

Insofar as the Company is aware, it knows of the following significant shareholders holding more than 3 per cent. of the Company’s issued share capital (last updated 14 July 2020).

Name Number of ordinary shares held % of issued share capital
Peter Keeling* 17,502,049 20.82%
Gresham House 9,443,000 11.23%
Canaccord Genuity Group Inc 7,808,750 9.29%
Elizabeth Considine 5,512,169 6.56%
Berenberg Bank 5,069,500 6.03%
Philip White** 3,026,330 3.6%
Herald Investment Mgt 3,011,000 3.58%
Ryan Keeling 2,890,643 3.44%
Total 54,263,441 64.55%

*includes 9,585,659 shares held by Delia Keeling, Peter’s wife prior to admission and 8,837,975 following admission
**includes 1,009,800 shares held by the Philip White Tyres Pension Trust 81810

 

Directors’ Shareholdings

Name Number of ordinary shares held % of issued share capital
Peter Keeling* 17,502,049 20.82%
Philip White** 3,026,330 3.60%
Ryan Keeling 2,890,643 3.44%
Julie Goonwardene Wallin 1,614,127 1.92%
Mike Wort 144,737 0.17%
Charles Hindson 43,500 0.05%
Total 25,221,386 30.00%

*includes 9,585,659 shares held by Delia Keeling, Peter’s wife prior to admission and 8,837,975 following admission
**includes 1,009,800 shares held by the Philip White Tyres Pension Trust 81810

 

Shares not in public hands
A total of 41.23% of the Company’s securities are not traded in public hands.

Statement of the Rights of Shareholders
The rights of shareholders are governed by UK law.

Restrictions in transfer of AIM securities
There are no restrictions on the transfer of the company’s ordinary shares.

UK City Code on Takeovers and Mergers
The Company is subject to the provisions of the City Code on Takeover and Mergers.

Other exchanges and trading platforms
Diaceutics PLC has not applied or agreed to have any of its securities admitted or traded on any other exchanges or platforms.

TR1 Notifications
To inform the Company of any notable changes in shareholding, please contact: investorrelations@diaceutics.com

Documents sent to Shareholders
Form of Proxy
Circular and notice of general meeting

Latest Corporate News / RNS Announcements

Latest Corporate News / RNS Announcements

Investor Alerts